Solitary Pulmonary Nodule — Viva Defence

Opening statement (SASPOP, delivered aloud)

"Mr Doyle is a 67-year-old ex-smoker with an incidental 11 mm spiculated solid nodule in the right upper lobe, on a background of severe emphysema and significant ischaemic heart disease with impaired ventricular function. His main problems are: a radiologically suspicious nodule whose malignancy probability is high enough that surveillance alone is not defensible; severely limited pulmonary reserve that makes both transthoracic biopsy hazardous and any resection marginal; cardiac comorbidity that compounds procedural risk; and acute anxiety about a possible cancer diagnosis. I would like to establish the nodule's temporal behaviour by finding prior imaging, quantify risk formally, characterise it with PET-CT, obtain tissue by the safest route — which in him is bronchoscopic, not percutaneous — and take every fork of this pathway through the lung nodule MDT with his preferences heard at each step." [1] [2]

Structured problem list

1. An 11 mm spiculated upper-lobe nodule in a heavy ex-smoker — above the 8 mm band, spiculated, apical: three malignant-leaning features before any model is opened, so this is a PET-and-tissue problem, not a surveillance one [1] [2].
2. Severe emphysema (FEV1 48%) — raises CT-guided biopsy pneumothorax risk into the highest stratum and threatens tolerance of any resection; it is also, usefully, a Brock variable that raises his pre-test probability [2] [4].
3. Ischaemic heart disease, EF 40%, prior NSTEMI — shapes anaesthetic risk, the wisdom of a thoracotomy, and the case for the least invasive diagnostic path [6].
4. No prior imaging yet located — the temporal question is unanswered; an old comparison could still change everything, in either direction [1].
5. Anxiety and an unanswered 'is it cancer?' — a problem in its own right, with its own management [1].

Integrated management plan

• Find every old image first — prior ED films, the pre-angiogram chest X-ray, anything from his cardiology admissions. Two-year stability would discharge a solid nodule; growth would settle the escalation. Zero cost, highest yield [1].
• Quantify risk formally — Brock probability from age, sex, emphysema, family history and the nodule's size, spiculation, upper-lobe location, type and count. He will land in the intermediate-to-high band; BTS would route him to PET at a Brock probability of 10% or more [2] [6].
• PET-CT next — to characterise avidity, screen nodes and distant sites, and target biopsy; at 11 mm the nodule is within PET's reliable range, and I quote sensitivity about 97% and specificity about 78% with the granuloma false-positive caveat [3].
• Tissue by the bronchoscopic route — his emphysema makes CT-guided biopsy dangerous (population data show pneumothorax in roughly one in five transthoracic biopsies, concentrated in older emphysematous patients); if a bronchus sign is present, navigational or radial-EBUS biopsy offers about 73% yield with pneumothorax of only a few percent — the right yield-for-safety trade in this chest [4] [5].
• MDT at every fork — the nodule meeting weighs his probability, his PET, his fitness and his wishes, and owns the surveillance-versus-biopsy-versus-resection call [6].
• Define operability honestly, early — pulmonary function with DLCO and predicted post-operative values, cardiology review, and the frank discussion that if this is a small peripheral cancer and he is borderline, the options span limited resection, stereotactic radiotherapy and surveillance-with-escape — chosen with him, not for him [6] [7].
• Manage the anxiety as a problem, not a side-effect — plain-language probability, a written plan with dates, a named contact, and a booked review rather than a vague 'we'll keep an eye on it' [1].

Probing questions with model answers

"Why not just send him for a CT-guided biopsy — it is the highest-yield needle?" — "Because yield is only half the equation. Transthoracic biopsy causes pneumothorax in roughly one in five procedures overall, and the risk concentrates in older patients with emphysema — precisely Mr Doyle. A man with FEV1 48% tolerates a tension pneumothorax badly. If his CT shows a bronchus sign, navigational or radial-EBUS biopsy gives me about 73% yield at a pneumothorax rate of a few percent; in this chest, that trade wins" [4] [5].

"What if the PET is negative?" — "At 11 mm a solid spiculated nodule is within PET's reliable range, so a negative scan lowers the probability meaningfully — but specificity is imperfect, indolent adenocarcinomas can be cold, and a spiculated nodule in a heavy ex-smoker keeps a residual risk that still needs an answer. I would take a negative PET back to the MDT for a surveillance-with-escape plan — short-interval thin-section CT — rather than discharge; negative PET lowers probability, it does not close the case" [3] [1].

"If tissue confirms a T1 adenocarcinoma, is he an operative candidate?" — "Borderline, and that is a physiological question, not a chronological one. FEV1 48% with an EF of 40% makes lobectomy high-risk, but the conversation is wider than yes-or-no: predicted post-operative lung function and DLCO, cardiology optimisation, and the modern reality that for small peripheral tumours up to 2 cm, segmentectomy achieved at least equivalent — in fact superior overall — survival to lobectomy in JCOG0802, which makes a limited resection thinkable where a lobectomy is not. If he is truly inoperable, stereotactic radiotherapy is the established curative-intent alternative. The MDT, the anaesthetist and Mr Doyle make that call together" [6] [7].

"He asks you directly: do I have cancer?" — "Honesty with the number and the plan: 'I don't know yet, and neither does anyone — what I can tell you is that nodules like this need an answer, that your smoking history and the nodule's appearance mean we take it seriously, and that there is a clear sequence — old scans, a PET scan, then a sample taken in the safest way for your lungs — and at the end of it we will know. If it is an early cancer, this is the stage at which treatment works best.' Then I stop talking and listen to what the question sits underneath" [1].

"Why did you not simply book a 3-month surveillance CT and review him in clinic?" — "Because Fleischner's options above 8 mm are 3-month CT, PET or tissue — and the choice between them is risk-weighted. An 11 mm spiculated upper-lobe nodule in a 45-pack-year ex-smoker with emphysema carries a Brock probability far above the band where watching is the thoughtful option; delay here is a decision, and it is the wrong one. Surveillance is a plan for low-probability nodules, not a deferral of high-probability ones" [1] [2].

"Does Fleischner even apply to him?" — "Yes — he is over 35, the nodule was incidental, he has no known cancer and he is not immunosuppressed, so the framework applies; it is the risk-weighting within it that drives him to PET and tissue. But I check those exclusions aloud every time, because the exam question that features a 28-year-old or a transplant patient is testing exactly that reflex" [1].

Communication points

• Probability is shareable: "most nodules this size turn out not to be cancer, and the suspicious features of yours mean we will prove which side yours is on" — neither false reassurance nor premature verdict [1].
• Every procedural recommendation carries its number: pneumothorax one in five for a transthoracic needle, a few percent for the bronchoscopic route — patients hear these as odds in their own life, and quoting them is consent, not detail [4] [5].
• His quit date is three years ago: protect it. Cessation support continues, framed as the single intervention that still changes his trajectory more than any scan [6].
• Shared decision-making is explicit at the operability fork: limited resection, radiotherapy or close surveillance each have a defensible logic in a borderline patient, and his priorities are data the MDT needs [6].